Peter Beitsch, MD/

New SERM, New era??

A new SERM - Z-Endoxifen has shown promise in a phase 1 study of 38 pts.  Stable disease >6m or partial responses were seen in 26% of patients and the maximum tolerated dose was not reached (1600mg/d max'ed out).  Endoxifen is the active metabolite of tamoxifen and therefore bypasses any issues surrounding CYP2D6 metabolism (which is required for tamoxifen).  A phase 2 trial will directly compare endoxifen (80 mg/day) with tamoxifen (20 mg/day) in women with prior aromatase inhibitor (AI) progression and is designed to understand the relationship between CYP2D6 genotype, endoxifen exposure, and the antitumor benefit of both drugs.  BOLOhttps://www.medpagetoday.com/HematologyOncology/BreastCancer/68893?xid=NL_breakingnews_2017-10-31&eun=g993671d0r

Leave A Comment